Institutional Validation Study Inferring 2% MGMT Methylation Positive Impact on Survival in Newly Diagnosed Glioblastoma (GBM) Patients

被引：0

作者：

Cappelli, L. ^{[1
]}

Poiset, S. J. ^{[2
]}

Khan, M. ^{[3
]}

Kayne, A. ^{[3
]}

Nelson, N. G. ^{[4
]}

Gardner, C. ^{[3
]}

Uppendahl, A. ^{[3
]}

Zhan, T. ^{[5
]}

Wang, Z. X. ^{[6
]}

Judy, K. ^{[7
]}

Andrews, D. W. ^{[8
]}

Alnahhas, I. ^{[9
]}

Shi, W. ^{[10
]}

机构：

[1] Thomas Jefferson Univ Hosp, Dept Radiat Oncol, Philadelphia, PA USA

[2] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Radiat Oncol, Philadelphia, PA USA

[3] Thomas Jefferson Univ Hosp, Sidney Kimmel Med Coll, Philadelphia, PA USA

[4] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Canc Ctr, Philadelphia, PA USA

[5] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA USA

[6] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA USA

[7] Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA USA

[8] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Neurosurg, Philadelphia, PA USA

[9] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA USA

[10] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Radiat Oncol, Philadelphia, PA USA

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2204

引用

页码：E92 / E93

页数：2

共 50 条

[1] MGMT methylation status may predict survival in elderly patients with newly diagnosed glioblastoma (GBM)
Gerstner, E. R.
Yip, S.
Wang, D. L.
Louis, D. N.
Iafrate, A. J.
Batchelor, T. T.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[2] MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Gerstner, E. R.
Yip, S.
Wang, D. L.
Louis, D. N.
Iafrate, A. J.
Batchelor, T. T.
[J]. NEUROLOGY, 2009, 73 (18) : 1509 - 1510
[3] Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study
Pinson, H.
Hallaert, G.
Van der Meulen, J.
Dedeurwaerdere, F.
Vanhauwaert, D.
Van den Broecke, C.
Van Dorpe, J.
Van Roost, D.
Kalala, J. P.
Boterberg, T.
[J]. JOURNAL OF NEURO-ONCOLOGY, 2020, 146 (01) : 55 - 62
[4] Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study
H. Pinson
G. Hallaert
J. Van der Meulen
F. Dedeurwaerdere
D. Vanhauwaert
C. Van den Broecke
J. Van Dorpe
D. Van Roost
J. P. Kalala
T. Boterberg
[J]. Journal of Neuro-Oncology, 2020, 146 : 55 - 62
[5] THE SIGNIFICANCE OF TERT PROMOTER MUTATIONS, TELOMERE LENGTH AND MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED AND RECURRENT IDH-WILDTYPE GLIOBLASTOMA (GBM): A LARGE MONO-INSTITUTIONAL STUDY
Lombardi, Giuseppe
Giunco, Silvia
Cavallin, Francesco
Angelini, Chiara
Caccese, Mario
Cerretti, Giulia
De Bonis, Pasquale
De Rossi, Anita
Zagonel, Vittorina
[J]. NEURO-ONCOLOGY, 2021, 23 : 15 - 15
[6] The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
Incekara, Fatih
Smits, Marion
van der Voort, Sebastian R.
Dubbink, Hendrik Jan
Atmodimedjo, Peggy N.
Kros, Johan M.
Vincent, Arnaud J. P. E.
van den Bent, Martin
[J]. FRONTIERS IN ONCOLOGY, 2020, 10
[7] FINAL RESULTS OF THE MGMT UNMETHYLATED ARM OF PARADIGM-2: A PHASE I STUDY OF OLAPARIB AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Derby, S. J.
Sweeting, L.
Shad, S.
Paterson, L.
Stobo, J.
Nowicki, S.
Williamson, A.
James, A.
Short, S. C.
McBain, C.
Herbert, C.
Powell, J.
Kelly, C.
Chalmers, A. J.
[J]. NEURO-ONCOLOGY, 2023, 25
[8] Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM).
Gorlia, T
Stupp, R
Eisenhauer, EA
Mirimanoff, RO
Van Den Bent, MJ
Belanger, K
Lacombe, D
Allgeier, A
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 859S - 859S
[9] PREDICTIVE VALUE OF MGMT PROMOTER (PMGMT) METHYLATION STATUS ON PSEUDOPROGRESSION (PSP) AND SURVIVAL ANALYSIS IN GLIOBLASTOMA (GBM) PATIENTS: A RETROSPECTIVE SINGLE INSTITUTIONAL ANALYSIS
Interno, V.
De Santis, P.
Stucci, L.
Porta, C.
[J]. NEURO-ONCOLOGY, 2021, 23 : 54 - 54
[10] MGMT PROMOTER METHYLATION STATUS IN NEWLY DIAGNOSED GLIOBLASTOMAS (GBM): RETROSPECTIVE ANALYSIS FROM A CLINICAL SERIES OF PATIENTS
Garcia, M. Martinez
Tortosa, A.
Maldonado, X.
Gonzalez, S.
Balana, C.
Gallego, O.
Verger, E.
Fuentes, R.
Navarro, V.
Gil, M. Gil
[J]. NEURO-ONCOLOGY, 2008, 10 (06) : 1126 - 1126

← 1 2 3 4 5 →